NasdaqCM - Nasdaq Real Time Price USD

Pulmatrix, Inc. (PULM)

Compare
6.01
+0.02
+(0.33%)
At close: January 10 at 4:00:00 PM EST
5.90
-0.11
(-1.83%)
After hours: January 10 at 5:43:50 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,005.00
7,298.00
6,071.00
5,169.00
12,634.00
Operating Expense
17,423.00
22,038.00
25,018.00
21,759.00
22,496.00
Operating Income
-7,418.00
-14,740.00
-18,947.00
-16,590.00
-9,862.00
Net Non Operating Interest Income Expense
586.00
867.00
309.00
7.00
82.00
Other Income Expense
-2,824.00
-248.00
-198.00
-3,588.00
-9,528.00
Pretax Income
-9,656.00
-14,121.00
-18,836.00
-20,171.00
-19,308.00
Net Income Common Stockholders
-9,656.00
-14,121.00
-18,836.00
-23,368.00
-19,308.00
Diluted NI Available to Com Stockholders
-9,656.00
-14,121.00
-18,836.00
-23,368.00
-19,308.00
Basic EPS
-2.64
-3.87
-5.46
-8.63
-13.43
Diluted EPS
-2.64
-3.87
-5.46
-8.63
-13.43
Basic Average Shares
3,652.29
3,651.91
3,447.70
2,708.56
1,437.67
Diluted Average Shares
3,652.29
3,651.91
3,447.70
2,708.56
1,437.67
Total Operating Income as Reported
-10,036.00
-14,740.00
-18,947.00
-20,167.00
-9,862.00
Total Expenses
17,423.00
22,038.00
25,018.00
21,759.00
22,496.00
Net Income from Continuing & Discontinued Operation
-9,656.00
-14,121.00
-18,836.00
-20,171.00
-19,308.00
Normalized Income
-7,038.00
-14,121.00
-18,836.00
-16,594.00
-10,019.00
Interest Income
586.00
867.00
309.00
7.00
82.00
Net Interest Income
586.00
867.00
309.00
7.00
82.00
EBIT
-7,418.00
-14,740.00
-18,947.00
-16,590.00
-9,862.00
EBITDA
-6,775.00
-13,265.00
-17,402.00
-15,354.00
-8,819.00
Reconciled Depreciation
643.00
1,475.00
1,545.00
1,236.00
1,043.00
Net Income from Continuing Operation Net Minority Interest
-9,656.00
-14,121.00
-18,836.00
-20,171.00
-19,308.00
Total Unusual Items Excluding Goodwill
-2,618.00
--
--
-3,577.00
-9,289.00
Total Unusual Items
-2,618.00
--
--
-3,577.00
-9,289.00
Normalized EBITDA
-4,157.00
-13,265.00
-17,402.00
-11,777.00
470.00
12/31/2020 - 3/21/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TENX Tenax Therapeutics, Inc.
6.24
-2.88%
 
BPTH Bio-Path Holdings, Inc.
0.9500
-2.92%
 
CAPR Capricor Therapeutics, Inc.
13.19
-4.83%
 
MDCLF MedinCell S.A.
6.98
0.00%
 
APVO Aptevo Therapeutics Inc.
4.7900
-3.82%
 
CLRB Cellectar Biosciences, Inc.
0.2823
-9.23%
 
GYRE Gyre Therapeutics, Inc.
9.99
+3.85%
 
BNTC Benitec Biopharma Inc.
11.00
-0.54%
 
MBRX Moleculin Biotech, Inc.
1.6400
-7.87%
 
AKTX Akari Therapeutics, Plc
1.2150
-5.08%